US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...

Merck's (MRK) new injectable version of Keytruda aims to overcome regulatory hurdles and market challenges, offering a more ...

Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...

In addition to the Phase 3 MK-3475A-D77 trial, Merck’s subcutaneous pembrolizumab clinical development program includes the ...

Through a first-of-its-kind report, the Canadian Mental Health Association (CMHA) is providing an in-depth look at the mental health system in Canada?with all its cracks and failings?and how people ...

Citi Trends Inc. today announced the Board of Directors has appointed Kenneth (Ken) Seipel as Chief Executive Officer, effective November 18, 2024. Mr. Seipel has been serving as the Interim CEO of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...

Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...

Merck is also conducting a late-stage trial of subcutaneous pembrolizumab alone, compared to intravenous Keytruda alone for treating patients with metastatic NSCLC whose tumors have high ...

The phase 3 trial met both primary pharmacokinetic endpoints. Topline results were announced from a phase 3 trial investigating a subcutaneous formulation of pembrolizumab, a programmed death receptor ...

The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...

Merck & Co. Inc. has in-licensed Lanova Medicines Ltd.’s PD-1/VEGF bispecific antibody LM-299 in a deal worth up to $2.7 billion in a move to bolster its Keytruda (pembrolizumab) fortress. Under terms ...